Chi-Med cuts surufatinib PhIII short; FDA greenlights Herceptin copycat from Amgen, Allergan
→ One of Chi-Med’s late-stage favorites is graduating early from its Phase III study, having met its primary endpoints at interim analysis. The Hong Kong-headquartered biotech left out the numbers in its brief statement, which noted that surufatinib hit a PFS goal among patients with extra-pancreatic neuroendocrine tumors. CEO Christian Hogg has tapped the drug, alongside savolitinib, for approvals over the next two years to follow up on the landmark OK for fruquintinib in China.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.